⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0342

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2023-04-02
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

severe assessed 2026-08-18

Grade 3 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 39); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 85); relationship: Y; serious criteria: hospitalization

severe assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-02-03 (study day 290); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-07 (study day 323); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-04-05 (study day 352); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-08-05 (study day 474); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-10-15 (study day 545); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.